CompletedPhase 2NCT03197662

Intranasal Oxytocin vs. Placebo for the Treatment of Hyperphagia in Prader-Willi Syndrome

Studying Prader-Willi syndrome

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Eric Hollander
Principal Investigator
Eric Hollander, MD
Albert Einstein College of Medicine
Intervention
Intranasal Oxytocin (IN-OXT)(drug)
Enrollment
32 enrolled
Eligibility
5-17 years · All sexes
Timeline
20182022

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03197662 on ClinicalTrials.gov

Other trials for Prader-Willi syndrome

Additional recruiting or active studies for the same condition.

See all trials for Prader-Willi syndrome

← Back to all trials